New drug may get heart surgery patients home days earlier

NCT ID NCT07357675

Not yet recruiting Symptom relief Sponsor: EBI Anti Sepsis BV Source: ClinicalTrials.gov ↗

First seen Jan 23, 2026 · Last updated May 20, 2026 · Updated 18 times

Summary

This study tests a new therapy called EA-230 to see if it helps people recover faster after coronary artery bypass surgery. In an earlier trial, those who received EA-230 spent less time in the ICU and hospital and had fewer serious problems. This larger Phase 3 trial will involve 300 participants and compare EA-230 to a placebo to confirm if it is safe and effective.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE (CAD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

MAYO clinic

Rochester, Minnesota, 55905, United States
Medisch Spectrum Twente

Enschede, Netherlands
RadboudUMC

Nijmegen, Netherlands
St Thomas' Hospital

London, United Kingdom
UZ Gent

Ghent, Belgium

Conditions

Explore the condition pages connected to this study.

CORONARY ARTERY BYPASS GRAFT SURGERY (CABG) CORONARY ARTERY BYPASS GRAFT SURGERY (CABG) CORONARY ARTERY DISEASE (CAD)